AML | Clinical

Ivosidenib Plus Azacitidine Improves Survival and Responses in IDH1-Mutated AML

September 29, 2022

Results from the phase 3 AGILE study presented at SOHO 2022 show that ivosidenib plus azacitidine prolong event-free and overall survival with good responses vs placebo in patients with IDH1-mutated acute myeloid leukemia